| United
States Patent |
5,676,977 |
| Antelman
|
October
14, 1997 |
Method of curing AIDS with
tetrasilver tetroxide molecular crystal devices
Abstract
The diamagnetic semiconducting molecular
crystal tetrasilver tetroxide (Ag.sub.4 O.sub.4) is utilized for destroying
the AIDS virus, destroying AIDS synergistic pathogens and immunity
suppressing moieties (ISM) in humans. A single intravenous injection of the
devices is all that is required for efficacy at levels of about 40 PPM of
human blood. The device molecular crystal contains two mono and two
trivalent silver ions capable of "firing" electrons capable of electrocuting
the AIDS virus, pathogens and ISM. When administered into the bloodstream,
the device electrons will be triggered by pathogens, a proliferating virus
and ISM, and when fired will simultaneously trigger a redox chelation
mechanism resulting in divalent silver moieties which chelate and bind
active sites of the entities destroying them. The devices are completely
non-toxic. However, they put stress on the liver causing hepatomegaly, but
there is no loss of liver function.
|
Inventors: |
Antelman;
Marvin S. (Rehovot, IL) |
|
Assignee: |
Antelman
Technologies Ltd. (Providence, RI)
|
|
Appl. No.: |
08/658,955 |
|
Filed: |
May 31,
1996 |
Related U.S. Patent Documents
| |
|
|
|
|
| |
Application
Number |
Filing Date |
Patent Number |
Issue Date |
| |
310859 |
Sep., 1994 |
|
|
| |
|
Current U.S. Class: |
424/618 ; 514/495 |
|
Current International Class: |
A61K 33/38 (20060101); A61K 033/38 () |
|
Field of Search: |
424/618 514/495 |
References Cited
[Referenced By]
U.S. Patent Documents
Other References
"Is The AIDS Virus A Science Fiction?" by Peter H. Duesberg and
Bryan J. Ellison, Policy Review, Summer 1990, pp. 40-51..
|
Primary Examiner: Hulina; Amy
Attorney, Agent or Firm:
Salter & Michaelson
Parent Case Text
This application is a continuation-in-part of patent application Ser. No.
08/310,859 filed Sep. 22, 1994, now abandoned.
Claims
What is claimed is:
1. A method of treating AIDS-afflicted humans comprising injecting a
multitude of tetrasilver tetroxide molecular crystals into the bloodstream
of the human subject.
2. A method for increasing white blood cell counts in AIDS-afflicted humans
comprising injecting a multitude of tetrasilver tetroxide molecular crystals
into the bloodstream of the human subject.
3. Methods of treating AIDS-affilicted humans according to claims 1-2 where
the concentration of said molecular crystals is approximately 40 PPM of the
total blood weight of the human subject.
Description
BACKGROUND OF THE INVENTION
The present invention relates to the employment of molecular crystals as
anti-AIDS devices, but more particularly to the molecular crystal
semiconductor tetrasilver tetroxide Ag.sub.4 O.sub.4 which has two
monovalent and two trivalent silver ions per molecule, and which through
this structural configuration enables intermolecular electron transfer
capable of killing viruses and binding them to the resulting silver entity
so that a single intravenous injection will completely obliterate acquired
immune deficiency syndrome (AIDS) in humans. Furthermore, said devices are
capable of killing pathogens and purging the bloodstream of immune
suppressing moieties (ISM) whether or not created by the AIDS virus (HIV);
so as to restore the immune system.
The present invention is based on concepts previously elucidated in
applicant's U.S. Pat. No. 5,336,499 which discloses the destruction and
inhibition of bacteria, algae and the AIDS virus in nutrient life supporting
systems by using said silver oxide devices. Example 3 of said patent
discloses that 18 PPM of said crystal devices could totally suppress the
AIDS virus (page 6, line 5). Subsequent to the filing of the aforementioned
patent, further testing revealed complete 100% destruction of the AIDS virus
in vitro at 20 PPM, and the fact that said devices were harmless when
ingested and inhaled, being non-toxic.
Encouraged by these evaluations and successes, applicant obtained permission
to evaluate the crystals in vitro against murine acquired immune deficiency
syndrome (MAIDS). Only one facility in the State of Israel is licensed for
these evaluations, namely, the Kaplan Hospital in Rehovot, Israel, which is
affiliated with the Hebrew University-Hadassah Medical School where said
evaluations were done.
The initial evaluations entailed experimenting with various silver moieties
cited in applicant's aforementioned patent, concentrations, non-reactive
buffers and modes of administration. After about 18 months of judicious
efforts and initial failures, success was finally achieved in destroying the
MAIDS virus in C57BL mice with a single intravenous injection. The results
of this test program comprise Example 5 of U.S. Pat. No. 5,336,499. After
success with mice, the inventor was able to test the efficacy of said
devices on two select etiological groups of terminal AIDS patients in a
clinic in Tegucigalpa, Honduras, Central America.
The AIDS patients comprised the etiological subgroups, Candidiasis and
Wasting Syndrome. Current indicator diseases for diagnosing AIDS which have
been expanded by the CDC, fall into the following five major categories with
the approximate percent distribution among AIDS patients:
______________________________________ 1. P. carinii pneumonia 51% 2.
Wasting syndrome 19% 3. Candidiasis 13% 4. Kaposi's sarcoma 11% 5. Dementia
6% ______________________________________
This invention concerns itself with the treatment and cure of candidiasis
and wasting syndrome AIDS patients with Tetrasil*. These two groups account
for approximately one third of AIDS cases.
Stedman's Medical Dictionary (Williams & Wilken's 26th Ed., 1995) defines
wasting syndrome "as a condition of 10% weight loss in conjunction with
diarrhea or fever . . . Associated with AIDS (p. 1744)."
OBJECTS OF THE INVENTION
The main object of the invention is to provide for a molecular scale device
of a single tetrasilver tetroxide crystalline molecule capable of restoring
the immunity of AIDS afflicted humans of the two AIDS etiological subgroups,
candidiasis and wasting syndrome.
Another object of the invention is to provide for immunity restoration in
said AIDS afflicted humans through a single injection.
Another object of this invention is to destroy ISM in humans manifesting
AIDS diseases of said AIDS etiological subgroups irrespective as to whether
said ISM was HIV induced, since it is known that humans may manifest AIDS
and still be HIV negative, and thus restore the immune system in said
humans.
Another object of this invention is to destroy the AIDS virus when present
in the systems of said AIDS afflicted humans.
SUMMARY OF THE INVENTION
This invention relates to a molecular scale device not only capable of
destroying the AIDS virus, but of purging the human bloodstream of pathogens
and restoring immunity to AIDS patients of the candidiasis and wasting
syndrome categories. Said molecular device consists of a single crystal of
tetrasilver tetroxide (Ag.sub.4 O.sub.4). The crystal lattice of this
molecule has a unique structure since it is a diamagnetic semiconducting
crystal containing two mono and two trivalent silver ions, which in effect
are capable of "firing" electrons under certain conditions which will
destroy AIDS viruses, other pathogens and immune suppressing moieties (ISM),
not only through the electrocution mode, but also by a binding process which
occurs simultaneously with electron firing, namely, binding and chelation of
divalent silver, i.e., the resulting product of the electron transfer redox
that occur when the monovalent silver ions are oxidized and the trivalent
ions are reduced in the crystal. The binding/chelation effect occurs at
active sites of the AIDS virus, pathogens and ISM. Because of the extremely
minute size of a single molecule of this crystal, several million of these
devices may be employed in concert to destroy a virus colony to purge a life
support system of ISM and pathogens with the consumption of only parts per
trillion of the crystal devices. Thus an optimum of 40 PPM of the devices by
weight of human blood was found to be sufficient to completely obliterate
AIDS. This concentration is slightly over double of the optimum
concentration recommended in applicant's aforementioned U.S. patent for the
destruction of the human AIDS virus in vitro. Other details concerning the
structure of the crystal and its mechanism against pathogens, the AIDS virus
and ISM would analogously hold here, and have already been further
elucidated in said patent.
The actual destruction of pathogens, ISM and the AIDS virus is effectuated
by injection of a suspension of these devices in distilled or deionized
water with a non-reacting electrolyte directly, i.e. intravenously, into the
bloodstream. A single injection is all that is required under these
conditions. Accordingly, humans injected in this manner, upon being
inspected after three weeks or more had elapsed and compared with similar
humans that had been given placebos, were completely cured of AIDS. The
control group still manifested AIDS. Accordingly, the tetrasilver tetroxide
device performed in concert with and in full conformity with the ultimate
objects of this invention. Furthermore, three out of four wasting syndrome
terminal patients and four out of the five candidiasis terminal patients
were still alive in 1995 after a year and a half had elapsed from their
initial injection. By that time all the AIDS patients had been released from
the clinic and allowed to return home.
Other objects and features of the present invention shall become apparent to
those skilled in the art when the present invention is considered in view of
the accompanying examples. It should, of course, be recognized that the
accompanying examples illustrate preferred embodiments of the present
invention and are not intended as a means of defining the limits and scope
of the present invention.
EXAMPLE 1
Five patients afflicted with AIDS of the candidiasis etiological category
were segregated for Tetrasil treatment. The rationale for selecting them was
based on facts presented in an article by Peter H. Duesberg and Brian J.
Ellison entitled "Is The AIDS Virus A Science Fiction?" (Policy Review,
Summer 1990 pp. 40-51). Only the factual presentations of the article were
utilized and the hypothesis of the authors was ignored. The facts presented
in the article related to the method of selecting AIDS patients based on the
five aforementioned etiological subgroups targeted by the CDC, and the
evidence presented, that there is AIDS without HIV as well as with it so
that an anti-viral agent in most instances will not necessarily restore the
immunity system.
Evaluations with Tetrasil were conducted on AIDS patients at Lucha Contra el
Sida, Comayaguela, Honduras. The patients two weeks prior to inoculation
were removed from their AZT, AIDS therapy. Tetrasil was administered at
approximately 40 PPM of blood volume per patient as a suspension in a
proprietary buffer solution (pH=6.5), supplied by Holipharm Corporation.
The results of evaluations with candidiasis are tabulated in Table I under
its disease category. All patients evaluated were terminal. Some, however,
were in moderate (m) condition and others in poor (p) as designated in the
Table. The I and F designations refer to initial and final values as shown.
WBC indicates white cell blood count. The H column, following CD 8,
indicates whether hepatomegaly occurred. This was an unfortunate consequence
of the treatment which resulted in enlarged livers in all patients except
the second one. Despite hepatomegaly, there was no interference with liver
function.
The onset of hepatomegaly was not spontaneous and varied from patient to
patient, being in the range of 4-16 days.
It should also be noted that shortly after injection of Tetrasil there were
indications of fever (symbolized by T in the Ag.sub.4 O.sub.4 column),
sometimes accompanied by fatigue (F). The body temperature was invariably
38.5.degree. C. (101.3.degree. F.). This was indicative of restoration of
the immune response of the body, since normally the body will destroy
pathogens when the immune system is functional by raising the temperature.
The patient who died; first responded favorably to Diflucan, which
previously gave no response. He was cured of his candidiasis, but
unfortunately succumbed to his previous body damage. All the other
candidiasis syndrome people who previously did not respond to the indicated
medications subsequently responded after the Tetrasil treatment. Further
evidence of the recovery of the AIDS patients manifested itself 30 days
after the initial injection when white blood cell counts were taken. They
are shown in Table I under the WBC column, which gives the initial and final
WBC. All candidiasis patients showed a dramatic increase in their white
blood cell counts, indicative of the restoration of their immunity systems.
EXAMPLE 2
The above protocol of Example 1 was repeated with AIDS patients exhibiting
wasting syndrome. The results of their treatment are tabulated in Table I
under the disease category of said syndrome. It should be noted that two of
the four wasting syndrome patients showed improved white blood counts. The
female patient, whose condition improved from poor and terminal to be among
the living, showed a decrease in the WBC. However, she showed an increase in
body temperature which was indicative of immune response. The test results
indicate that one cannot rely on a single factor to indicate the demise of
AIDS. The usual HIV marker CD 4 initial and final are irrelevant. ISM
suppression appears to be more critical than the destruction of HIV. AIDS
was suppressed, any permanent damage that had been done to the patients in
the course of their succumbing to AIDS was not obviously cured or corrected
by said crystal device treatment, rather said injury persisted and the
patient was improved with respect to AIDS but still suffered from said
permanent injury or impairment previously inflicted.
TABLE I
__________________________________________________________________________
Response of AIDS Patients to Single 40 PPM
Ag.sub.4 O.sub.4 Inoculation Date Weight DISEASE PATIENT Inoc. WBC CD 4
DEATH Lbs. Group Sex Age Medictn 1994 I F I F CD 8 H 1944 I F Ag.sub.4
O.sub.4
__________________________________________________________________________
Candidiasis M p 28 Diflucan 5/5 1,200 4,200 41
-- 221 + 6/11 82 76 T F m 33 " 5/5 6,000 6,700 554 872 394 - 98 98 T F m 33
Ketaconzl 5/27 2,600 3,850 248 181 951 + 123 123 T M p 62 " 6/2 3,300 3,700
89 237 59 + 105 92 F F m 31 Pentamidn 6/2 2,400 3,050 9 181 65 + 121 118
Pain Wasting M m 27 5/27 3,600 4,600 39 14 709 + 119 120 T Syndrome M m 28
5/27 2,750 -- 10 -- 60 + 7/19 121 119 T, F F p 43 5/27 3,600 2,700 68 246
248 + 101 98 T, F M m 19 5/10 3,850 5,400 137 36 48 + 103 106 T, F
__________________________________________________________________________
As this invention may be embodied in several forms without departing from
the spirit or essential characteristics thereof, the present embodiments are
therefore illustrative and not restrictive, since the scope of the invention
is defined by the appended claims rather than by the description preceding
them, and all changes that fall within the metes and bounds of the claims or
that form their functional as well as conjointly cooperative equivalents,
are therefore intended to be embraced by these claims.
SOURCE:
United States Patent: 5676977
